The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors.
 
Toshio Shimizu
Consulting or Advisory Role - Abbvie; Daiichi Sankyo; Takeda
Speakers' Bureau - Chugai Pharma; Lilly
Research Funding - 3D Medicines (Inst); Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chordia Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); SymBio Pharmaceuticals (Inst); Takeda/Millennium (Inst)
Travel, Accommodations, Expenses - Takeda
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Takafumi Koyama
Honoraria - Chugai Pharma; Sysmex
Research Funding - PACT Pharma (Inst)
 
Yuki Katsuya
No Relationships to Disclose
 
Jun Sato
No Relationships to Disclose
 
Noriko Fukuhara
Honoraria - Chugai Pharma; SymBio Pharmaceuticals
Research Funding - AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Chugai Pharma (Inst); Genmab (Inst); HUYA Bioscience International; Incyte (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst); Takara Bio (Inst)
 
Hisayuki Yokoyama
Research Funding - Astellas Pharma
 
Hiroatsu Iida
Honoraria - Abbvie; Astellas Pharma; Chugai Pharma; Janssen; Novartis
Research Funding - Bristol-Myers Squibb; Chugai Pharma; Ono Pharmaceutical
 
Koji Ando
No Relationships to Disclose
 
Suguru Fukuhara
Speakers' Bureau - Chugai Pharma; Janssen; Otsuka; Takeda; Zenyaku Kogyo
Research Funding - Chugai Pharma; IQvia
 
Hiroshi Miyake
Employment - Chordia Therapeutics
Leadership - Chordia Therapeutics
Stock and Other Ownership Interests - Chordia Therapeutics
Travel, Accommodations, Expenses - Chordia Therapeutics
 
Yasushi Tanoue
Employment - Chordia Therapeutics; Eisai
 
Hirokazu Tozaki
Employment - Chordia Therapeutics; Kyowa Kirin
Stock and Other Ownership Interests - Chordia Therapeutics
Patents, Royalties, Other Intellectual Property - Kyowa Kirin (I)
 
Akio Mizutani
Employment - Chordia Therapeutics
Stock and Other Ownership Interests - Chordia Therapeutics
 
Daisuke Morishita
Employment - Chordia Therapeutics
Leadership - Chordia Therapeutics
Stock and Other Ownership Interests - Chordia Therapeutics
 
Kunihiko Takeyama
Employment - Chordia Therapeutics
Leadership - Chordia Therapeutics
Stock and Other Ownership Interests - Chordia Therapeutics
Consulting or Advisory Role - Chordia Therapeutics
Other Relationship - Flatiron Health
 
Noboru Yamamoto
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; Ono Pharmaceutical; Pfizer; Sysmex
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Otsuka; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)